Viral Outbreaks Highlight NNVC’s Antiviral Breakthrough

Unsubscribe

Sponsored content from Equiscreen

Tiny Biotech Firm NNVC Stands Out in a World Facing a Viral Epidemic Wave — Broad-Spectrum NV-387 Targets Viruses Killing Children and Adults Alike!

Viruses are wreaking havoc across the globe—this flu season has already caused millions of infections, RSV is killing children, and measles cases are forcing public health warnings.

Amid this mounting crisis, NanoViricides (NYSE: NNVC) is quietly developing NV-387, a broad-spectrum antiviral that has proven in animal studies to cure RSV, outperform Tamiflu and Xofluza against influenza, and target coronaviruses, smallpox, and MPox.

NV-387 completed Phase I with no adverse events and is now cleared to start a Phase II Mpox trial in the Democratic Republic of Congo, a major milestone that puts NNVC in the spotlight!

Investors should be paying attention now: NNVC isn’t just another biotech—it’s a potential game-changer in antiviral therapy,creating the first truly broad-spectrum treatment that viruses cannot escape.

With regulatory approvals in place and a platform that could target over 90% of human pathogenic viruses, NNVC represents a rare opportunity in the highly watched biotech space.

See why NNVC is the breakout biotech every investor needs to have on their radar

Today’s Bonus News

The Aging of America Could Make HCA Healthcare a Long-Term Winner

Submitted by Nathan Reiff. Published: 3/8/2026. 

Elderly patient reviewing tablet with nurse in clinic waiting room, symbolizing rising healthcare demand from aging

Key Points

  • HCA Healthcare has strong earnings growth, volume gains, and adjusted EBITDA gains, among other metrics, revealing strong fundamentals despite coming up short of analyst revenue estimates last quarter.
  • The company’s 2026 guidance suggests room to grow in several areas, though threats remain.
  • HCA’s recent rally may leave little room for short-term growth, but the stock could appeal to investors with longer-term healthcare demand trends in mind.
  • Special Report: Top hedge funds rely on this phenomenon to build their portfolios (From ProsperityPub)

Shifting demographics in the United States mean that adults of retirement age or older will outnumber minors sometime in the coming decade. That growing population will require substantial spending on healthcare — a long-term structural tailwind that could create opportunities for investors who can take a multiyear view.

HCA Healthcare (NYSE: HCA) stands to be a primary beneficiary of this trend due to its large network of hospitals, surgery centers, urgent care locations and other facilities. The company is already seeing strong demand and utilization trends, and investors focused on the sector’s longer-term transformation may increasingly view HCA as an attractive buy.

A Mixed Earnings Report Masks Fundamental Strengths

Elon Musk already made me a “wealthy man” (Ad)

I Met Elon Musk “Face-to-Face” 

During a private gathering of Wall Street elites, I was one of two people selected to speak with Elon personally.

As a result, my research now leads me to believe Elon will announce the SpaceX IPO on this date:

March 26, 2026. Circle it on your calendar.

I’m sharing an “access code” that lets anyone grab a pre-IPO stake before it happens. This is your invitation to the biggest wealth-building event of the decade.Click Here to See how to Get Your “SpaceX Access Code”

HCA’s latest earnings report for Q4 2025, like those from many other healthcare firms, was mixed. The company comfortably beat analyst expectations for earnings per share (EPS), reporting $8.01 — an improvement of nearly 29% versus the $7.37 consensus.

That said, revenue growth of 6.7% year-over-year (YOY) was more modest than anticipated. Analysts had forecast quarterly revenue of $19.7 billion; the company missed that target by about $158 million.

Although revenue momentum was slower than some expected — reflecting policy headwinds, the expiration of premium tax credits and changes in uninsured rates, among other factors — the quarter still revealed several underlying strengths. HCA reported its 19th consecutive quarter of volume growth, adjusted EBITDA rose 11% YOY, and adjusted EBITDA margin improved by 80 basis points.

Patients are using HCA facilities at record rates, with roughly 47 million patient encounters in 2025 helping drive a 20% improvement in operating cash flow for the year.

Signs of Potential From HCA’s Guidance

One factor that may appeal to investors is HCA’s forward guidance. For 2026, management expects revenue of $76.5 billion to $80 billion and adjusted EBITDA of $15.55 billion to $16.45 billion. Diluted EPS is projected at $29.10 to $31.50.

HCA has also increased its capital plans, raising expected capital expenditures (CapEx) to as much as $5.5 billion and announcing a $10 billion share repurchase program. Current shareholders received a dividend increase as well: HCA raised its quarterly payout by 8.3% to $0.78, a yield of about 0.54% and a payout ratio near 10.15%.

Management’s outlook is supported by improving admissions trends. The company reported a 2.4% YOY improvement in same-facility admissions in the quarter and a 2.9% increase in same-facility revenue per equivalent admission. For 2026, HCA expects equivalent admissions to rise another 2% to 3%.

The Risks Remaining For HCA

HCA’s momentum does not eliminate risk. Executives expect an adverse impact to adjusted EBITDA in 2026 of $600 million to $900 million tied to changes in health insurance exchanges. State supplemental payments could also be a drag, with an expected decline in supplemental net benefits of $250 million to $450 million for the year.

The company is taking steps to offset some of these pressures through a $400 million resiliency program focused on improving revenue integrity and capacity management while applying cost-discipline measures, including investments in AI and digital tools. How effective those initiatives will be remains to be seen.

Still, Wall Street appears reasonably optimistic about HCA’s ability to navigate a challenging external environment. Analysts expect earnings to increase by more than 12% next year, and roughly two-thirds of the 25 analysts covering HCA have assigned a Buy or equivalent rating. Several analysts have already raised price targets or reiterated bullish views in 2026.

With nearly 14% capital appreciation year-to-date in 2026, HCA’s near-term upside may be constrained. But given the anticipated long-term growth in healthcare demand, the company could be a compelling long-term investment for patient investors.

This email message is a sponsored message from Equiscreen, a third-party advertiser of MarketBeat. Why did I receive this email?. 


This message is a paid advertisement for Nanoviricides (NNVC) from Equiscreen and Interactive Offers. MarketBeat Media, LLC receives a fixed fee for each subscriber that clicks on a link in this email, totaling up to $14,000. Other than the compensation received for this advertisement sent to subscribers, MarketBeat and its principals are not affiliated with either Equiscreen or Interactive Offers. MarketBeat and its principals do not own any of the stocks mentioned in this email or in the article that this email links to. Neither MarketBeat nor its principals are FINRA-registered broker-dealers or investment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from MarketBeat to buy or sell any security. MarketBeat has not evaluated the accuracy of any claims made in this advertisement. MarketBeat recommends that investors do their own independent research and consult with a qualified investment professional before buying or selling any security. Investing is inherently risky. Past-performance is not indicative of future results. Please see the disclaimer regarding Nanoviricides (NNVC) on Interactive Offers’ website for additional information about the relationship between Interactive Offers and Nanoviricides (NNVC).


If you need assistance with your account, please don’t hesitate to email MarketBeat’s South Dakota based support team at contact@marketbeat.com.

If you would no longer like to receive promotional emails from MarketBeat advertisers, you can unsubscribe or manage your mailing preferences here.

© 2006-2026 MarketBeat Media, LLC. 
345 N Reid Place, Sixth Floor, Sioux Falls, South Dakota 57103. USA..

From Our Partners: In 50 years of analyzing silver, I’ve never seen anything like this (From The Oxford Club)

Unknown's avatar

Published by RJ Hamster

I was born on 6 August 1956 in San Francisco, California to Janet and (the late) Richard Hovis. I grew up in Santa Monica, California where I attended elementary, junior high school, and high school (graduating in 1974), in addition to involvement in sports and recreation (Little League +, the Boy’s Club ++). Further, it was in elementary school – St. Augustine’s By-the -Sea Parish School that I found, and made the choice to truly journey with God. I attended Arizona State University from 1974 to 1977 – seeking to become an architect, however, I was not accepted, and, as such, I graduated with a Liberal Arts degree. Upon graduation from Arizona State University, I attended Cal Poly San Luis Obispo and studied City and Regional Planning at the Master’s level. I successfully completed one (1) year in a two (2) year program – I did not complete the Master’s degree in City and Regional Planning – due to personal reasons. I returned to Santa Monica where I started (October 1979) my career as graphic designer with Exxon Company, USA. I spent five years with Exxon Company, USA. While working with Exxon Company, USA I was accepted into architectural school – Sci-Arc in Southern California, however, I did not attend preferring to stay with Exxon.. In 1982 I married Laura Flosi and in April 1983 we had our one and only child – Lauren Alain Hovis – a gift from God. We moved to Phoenix, Arizona in 1984 from Los Angeles, where I went to work as a graphic designer with Kitchell CEM (from 1985 -1987). From 1987 – 1995 I was an independent contractor, and a registered representative in mortgage finance, financial management, graphic design, and drafting. Further, I attended the University of Phoenix and successfully obtained a Master’s in Business Administration (MBA) in 1982. I was also a member of the Scottsdale Jaycees, where I became very involved in community events and projects. In 1994, I accepted a cartography position with the Defense Mapping Agency in Reston, Virginia. As such, I relocated from Phoenix to Reston. In 1998, I was accepted and worked as a Visual Information Officer with the Central Intelligence Agency. In 2002, I worked as a Support Officer until my retirement (due to a need for shoulder surgery) in September 2018. Away from my Federal Government service, I have been involved in various organizations and activities in Northern Virginia. In November of 2011, I married Rebecca Ouellette in Santa Monica, California. I reside in San Tan Valley, AZ with my two hamster - Jess and Timothy, our fish, our lizard - RJ Lizard., and our cats - Pearl and Grey. As to hobbies, I enjoy playing sports, attending sporting events, mentoring individuals from financial management to hamsters, building models, photography, travel, multimedia design, managing partner for RJ Hamster, and jazz – smooth jazz to a samba or a bossa nova. Love and God Bless, Peter – aka RJ Hamster Jo hi

Leave a Comment